Bibliography
- Alberti A , BenvegnuL: Management of hepatitis C.J. Hepatol.38(Suppl. 1), S104–S118 (2003).
- Lai MY , KaoJH, YangPM et al.: Long-term efficacy of ribavirin plus interferon α in the treatment of chronic hepatitis C. Gastroenterology111, 1307–1312 (1996).
- Lauer GM , WalkerBD: Hepatitis C virus infection.N. Engl. J. Med.345, 41–52 (2001).
- Manns MP , McHutchisonJG, GordonSC et al.: Peginterferon α2b plus ribavirin compared with interferon α2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet358, 958–965 (2001).
- Fried MW , ShiffmanML, ReddyKR et al.: Peginterferon α2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med.347, 975–982 (2002).
- Bacon BR : Managing hepatitis C.Am. J. Manag. Car.10(2 Suppl.), S30–S40 (2004).
- Hwang Y , SuC, ChenDS, ChenPJ: Prospect of individualized medicine in chronic hepatitis C therapy by pharmacogenomics.Current Pharmacogenomics4, 157–167 (2006).
- Fried MW : Viral factors affecting the outcome of therapy for chronic hepatitis C.Rev. Gastroenterol. Disord.4(Suppl. 1), S8–S13 (2004).
- Bruno R , SacchiP, MaiocchiL, ZocchettiC, FiliceG: Host factors affecting the outcome of treatment of hepatitis C.Rev. Gastroenterol. Disord.4(Suppl. 1), S3–S7 (2004).
- Tang J , KaslowRA: Pharmacogenomic perspectives of chronic hepatitis C virus (HCV) infection.Pharmacogenomics J4, 171–174 (2004).
- Suzuki F , AraseY, SuzukiY et al.: Single nucleotide polymorphism of the MXA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J. Viral Hepat.11, 271–276 (2004).
- Hijikata M , OhtaY, MishiroS: Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon.Intervirology43, 124–127 (2004).
- Yee LJ , TangJ, GibsonAW, KimberlyR, Van Leeuwen DJ, Kaslow RA: Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology33, 708–712 (2001).
- Andrade J r DR, Andrade DR: The influence of the human genome on chronic viral hepatitis outcome. Rev. Inst. Med. Trop. Sao Paulo46, 119–126 (2004).
- Hwang Y , ChenKD, ChangCW, ChenJL: SNP genotype modeling – pharmacogenomic approach for studying hepatitis C treatment. International Liver Congress, Hong Kong, p96–97 (2004).
- Kessler HH , SantnerB, UmlauftF et al.: Detection of hepatitis C viral sequences in serum by 'nested' polymerase chain reaction (PCR) and a commercial single-round PCR assay. Clin. Diagn. Virol.4, 239–250 (1995).
- Stephens M , SmithNJ, DonnellyP: A new statistical method for haplotype reconstruction from population data.Am. J. Hum. Genet.68, 978–989 (2001).
- Zheng B , AgrestiA: Summarizing the predictive power of a generalized linear model.Stat. Med.19, 1771–1781 (2000).
- Hoofnagle JH : Management of hepatitis C: current and future perspectives.J. Hepatol.31(Suppl. 1), 264–268 (1999).
- Chen L , BorozanI, FeldJ et al.: Hepatic gene expression discriminates responders and non-responders in treatment of chronic hepatitis C viral infection. Gastroenterology128, 1437–1444 (2005).
- Jayan GC , CaseyJL: Increased RNA editing and inhibition of hepatitis Δ virus replication by high-level expression of ADAR1 and ADAR2.J. Virol.76, 3819–3827 (2002).
- Thornton AM , BullerRM, DeVicoAL, WangIM, OzatoK: Inhibition of human immunodeficiency virus type 1 and vaccinia virus infection by a dominant negative factor of the interferon regulatory factor family expressed in monocytic cells.Proc. Natl Acad. Sci. USA93, 383–387 (1996).
- Weisz A , MarxP, SharfR et al.: Human interferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes. J. Biol. Chem.267, 25589–25596 (1999).
- Kitamura A , TakahashiK, OkajimaA, KitamuraN: Induction of the human gene for p44, a hepatitis C-associated microtubular aggregate protein, by interferon-α/β.Eur. J. Biochem.224, 877–883 (1994).
- Airoldi A , ZavagliaC, SiliniE et al.: Lack of a strong association between HLA class II, tumour necrosis factor and transporter associated with antigen processing gene polymorphisms and virological response to α-interferon treatment in patients with chronic hepatitis C. Eur. J. Immunogenet.31, 259–265 (2004).
- Sugimoto Y , KuzushitaN, TakeharaT et al.: A single nucleotide polymorphism of the low molecular mass polypeptide seven gene influences the interferon response in patients with chronic hepatitis C. J. Viral Hepat.9, 377–384 (2002).
- Kuzushita N , SugimotoY, SasakiY, Hayashi N: Involvement of TAP2and LMP7 gene polymorphisms in HCV infection. Nippon Rinsho59, 1248–1253 (2001).
- Ulloa L , DoodyJ, MassagueJ: Inhibition of TGFβ/SMAD signal transduction by the interferon-γ/STAT pathway.Nature397, 710–713 (1999).
- Kretzschmar M , DoodyJ, MassagueJ: Opposing BMP and EGF signaling pathways converge on the TGF-β family mediator Smad1.Nature389, 618–622 (1997).
- Wurthner JU , FrankDB, FeliciA et al.: Transforming growth factor-β receptor-associated protein 1 is a Smad4 chaperone. J. Biol. Chem.276, 19495–19502 (2001).
- Caronia S , McGarveyMJ, GoldinRD, FosterGR: Negative correlation between intrahepatic expression of hepatitis C antigens and apoptosis despite high-level expression of Fas and HLA antigens.J. Viral Hepat.11, 511–518 (2004).
- Zhu LX , LiuJ, XieYH et al.: Expression of hepatitis C virus envelope protein 2 induces apoptosis in cultured mammalian cells. World J. Gastroenterol.10, 2972–2978 (2004).
- Prikhod'ko EA , Prikhod'koGG, SiegelRM, ThompsonP, MajorME, CohenJI: The NS3 protein of hepatitis C virus induces caspase-8-mediated apoptosis independent of its protease or helicase activities.Virology329, 53–67 (2004).
- Munday NA , VaillancourtJP, AliA et al.: Molecular cloning and pro-apoptotic activity of ICErelII and ICErelIII, members of the ICE/CED-3 family of cysteine proteases. J. Biol. Chem.270, 15870–15876 (1995).
- Faucheu C , BlanchetAM, Collard-Dutilleul V, Lalanne JL, Diu-Hercend A: Identification of a cysteine protease closely related to interleukin-1 b-converting enzyme. Eur. J. Biochem.236, 207–213 (1996).
- Jin-no K , TanimizuM, HyodoI, Kurimoto F, Yamashita T: Plasma level of basic fibroblast growth factor increases with progression of chronic liver disease. J. Gastroenterol.32, 119–121 (1997).
- Jung J , ZhengM, GoldfarbM, ZaretKS: Initiation of mammalian liver development from endoderm by fibroblast growth factors.Science284, 1998–2003 (1999).
- Jensen DM , MorganTR, MarcellinP et al.: Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy. Hepatology43, 954–960 (2006).